Shire PLC Company Profile (NASDAQ:SHPG)

About Shire PLC (NASDAQ:SHPG)

Shire PLC logoShire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases. Its Hematology products include ADVATE (Antihemophilic Factor (Recombinant)), ADYNOVATE/ADYNOVI (Antihemophilic Factor (Recombinant), PEGylated)), RIXUBIS (Coagulation Factor IX (Recombinant)), VONVENDI (von Willebrand factor (Recombinant)) and FEIBA (Anti-Inhibitor Coagulant Complex). Its Genetic Diseases products include CINRYZE (C1 esterase inhibitor (human)), FIRAZYR (icatibant), ELAPRASE (idursulfase), REPLAGAL (agalsidase alfa) and VPRIV (velaglucerase alfa).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:SHPG
  • CUSIP: N/A
  • Web: www.shire.com
Capitalization:
  • Market Cap: $50.84391 billion
  • Outstanding Shares: 297,854,000
Average Prices:
  • 52 Week Range: $158.54 - $209.22
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 10.31
  • P/E Growth: 0.00
Dividend:
  • Annual Dividend: $0.91
  • Dividend Yield: 0.5%
Profitability:
  • Net Margins: 2.14%
  • Return on Equity: 13.05%
  • Return on Assets: 5.64%
Debt:
  • Debt-to-Equity Ratio: 0.66%
  • Current Ratio: 1.01%
  • Quick Ratio: 0.54%
Misc:
  • Beta: 1.6
 
Frequently Asked Questions for Shire PLC (NASDAQ:SHPG)

What is Shire PLC's stock symbol?

Shire PLC trades on the NASDAQ under the ticker symbol "SHPG."

How often does Shire PLC pay dividends? What is the dividend yield for Shire PLC?

Shire PLC announced a dividend on Friday, February 24th. Shareholders of record on Friday, March 10th will be given a dividend of $0.771 per share on Tuesday, April 25th. The ex-dividend date of this dividend is Wednesday, March 8th. This is a positive change from Shire PLC's previous dividend of $0.14. View Shire PLC's Dividend History.

How were Shire PLC's earnings last quarter?

Shire PLC (NASDAQ:SHPG) announced its quarterly earnings results on Tuesday, May, 2nd. The company reported $3.63 earnings per share for the quarter, beating the Zacks' consensus estimate of $3.22 by $0.41. The business had revenue of $3.57 billion for the quarter. Shire PLC had a return on equity of 13.05% and a net margin of 2.14%. The business's quarterly revenue was up 109.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.12 earnings per share. View Shire PLC's Earnings History.

When will Shire PLC make its next earnings announcement?

Shire PLC is scheduled to release their next quarterly earnings announcement on Thursday, August, 3rd 2017. View Earnings Estimates for Shire PLC.

What guidance has Shire PLC issued on next quarter's earnings?

Shire PLC issued an update on its FY17 earnings guidance on Tuesday, May, 2nd. The company provided earnings per share guidance of $14.60-15.20 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $15.00. The company issued revenue guidance of $14.5-14.8 billion, compared to the consensus revenue estimate of $15.23 billion.

Where is Shire PLC's stock going? Where will Shire PLC's stock price be in 2017?

20 equities research analysts have issued 12-month target prices for Shire PLC's stock. Their predictions range from $159.00 to $325.00. On average, they anticipate Shire PLC's share price to reach $224.90 in the next twelve months. View Analyst Ratings for Shire PLC.

What are analysts saying about Shire PLC stock?

Here are some recent quotes from research analysts about Shire PLC stock:

  • 1. According to Zacks Investment Research, "The approval of Mydayis is likely to boost Shire’s ADHD segment dominance while strong performance of Vyvanse, Cinryze and Elaprase will continue to drive Shire’s top line. The label expansion of Cinryze in paediatrics and conditional approval of Natpara in Europe should continue to drive the top line going ahead. The hematology and immunology segment, acquired from Baxalta, gave a major boost to product sales. The approval of Xiidra has boosted the company’s ophthalmology space, acquiring roughly 22% of the total market by the end of Mar 2017. The Dyax acquisition has integrated well and Shire announced positive results from the phase III trial on lanadelumab in May 2017. However, the adult ADHD space is one of the largest and fastest growing segments of the market but is highly genericized. Earnings estimates have fallen lately ahead of the Q2 results. Shire has a positive record of earnings surprises in the recent quarters." (7/17/2017)
  • 2. Jefferies Group LLC analysts commented, "SHPG posted strong 4Q16 revs ($3.8B vs $3.7B JEF) and EPS ($3.37 vs $3.26 JEF) as nearly all core franchises performed well. In particular, GI and Orphan Diseases showed strength. As for legacy BXLT, Immunoglobulins and Hemophilia performed well while Inhibitors lagged. We like the setup for 2017. If mgt executes on core brands, the Xiidra launch, and the BXLT integration, we could envision share price outperformance, augmented by significant deleveraging." (2/17/2017)

Are investors shorting Shire PLC?

Shire PLC saw a increase in short interest in July. As of July 14th, there was short interest totalling 1,247,044 shares, an increase of 34.9% from the June 30th total of 924,373 shares. Based on an average daily volume of 1,330,164 shares, the days-to-cover ratio is currently 0.9 days.

Who are some of Shire PLC's key competitors?

Who are Shire PLC's key executives?

Shire PLC's management team includes the folowing people:

  • Flemming Ornskov M.D., Chief Executive Officer, Executive Director
  • Jeffrey Poulton, Chief Financial Officer, Executive Director
  • William Mordan, General Counsel, Company Secretary
  • Perry Sternberg, Head - U.S. Commercial
  • Kim Stratton, Head - International Commercial
  • Philip J. Vickers, Head - Research and Development
  • Matthew Walker, Head - Technical Operations
  • Susan Saltzbart Kilsby, Independent Non-Executive Chairman of the Board
  • Olivier Bohuon, Non-Executive Director
  • Ian T. Clark, Non-Executive Director

Who owns Shire PLC stock?

Shire PLC's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Rockefeller Financial Services Inc. (0.00%), Kornitzer Capital Management Inc. KS (0.06%), Johnston Asset Management LLC (0.06%), Selz Capital LLC (0.03%), Aperio Group LLC (0.00%) and Eagle Global Advisors LLC (0.02%). View Institutional Ownership Trends for Shire PLC.

Who sold Shire PLC stock? Who is selling Shire PLC stock?

Shire PLC's stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Rockefeller Financial Services Inc., Quantitative Systematic Strategies LLC, Bank of Montreal Can, Catawba Capital Management VA, Leavell Investment Management Inc., Braun Stacey Associates Inc. and Private Trust Co. NA. View Insider Buying and Selling for Shire PLC.

Who bought Shire PLC stock? Who is buying Shire PLC stock?

Shire PLC's stock was acquired by a variety of institutional investors in the last quarter, including Kornitzer Capital Management Inc. KS, Johnston Asset Management LLC, Selz Capital LLC, Gateway Investment Advisers LLC, Osborne Partners Capital Management LLC, Great West Life Assurance Co. Can, US Bancorp DE and Heritage Investors Management Corp. View Insider Buying and Selling for Shire PLC.

How do I buy Shire PLC stock?

Shares of Shire PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Shire PLC's stock price today?

One share of Shire PLC stock can currently be purchased for approximately $168.29.


MarketBeat Community Rating for Shire PLC (NASDAQ SHPG)
Community Ranking:  3.6 out of 5 (  )
Outperform Votes:  771 (Vote Outperform)
Underperform Votes:  305 (Vote Underperform)
Total Votes:  1,076
MarketBeat's community ratings are surveys of what our community members think about Shire PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Shire PLC (NASDAQ:SHPG) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Hold Ratings, 15 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $224.90 (33.64% upside)

Analysts' Ratings History for Shire PLC (NASDAQ:SHPG)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/26/2017Piper Jaffray CompaniesSet Price TargetHold$159.00MediumView Rating Details
7/17/2017BTIG ResearchReiterated RatingBuy$242.00LowView Rating Details
7/13/2017Sanford C. BernsteinReiterated RatingMarket Perform$210.00LowView Rating Details
7/12/2017Stifel NicolausReiterated RatingBuy$245.00LowView Rating Details
7/11/2017Cantor FitzgeraldSet Price TargetBuy$222.00MediumView Rating Details
7/6/2017HSBC Holdings plcUpgradeReduce -> HoldMediumView Rating Details
6/9/2017Jefferies Group LLCReiterated RatingBuy -> Buy$239.00 -> $216.00LowView Rating Details
6/8/2017Royal Bank Of CanadaSet Price TargetBuy$218.00LowView Rating Details
6/1/2017Liberum CapitalDowngradeBuy -> HoldLowView Rating Details
5/31/2017Cowen and CompanyReiterated RatingOutperform$325.00LowView Rating Details
4/17/2017Goldman Sachs Group, Inc. (The)Boost Price TargetOverweight$202.00 -> $214.00LowView Rating Details
3/7/2017Barclays PLCInitiated CoverageOverweightN/AView Rating Details
2/17/2017GuggenheimReiterated RatingNeutralN/AView Rating Details
12/2/2016Societe GeneraleInitiated CoverageBuyN/AView Rating Details
11/14/2016Leerink SwannSet Price TargetBuy$198.00N/AView Rating Details
11/7/2016J P Morgan Chase & CoReiterated RatingOverweightN/AView Rating Details
11/3/2016Citigroup Inc.Reiterated RatingBuyN/AView Rating Details
11/2/2016Deutsche Bank AGReiterated RatingBuyN/AView Rating Details
10/23/2016BNP ParibasReiterated RatingBuyN/AView Rating Details
10/8/2016Shore CapitalReiterated RatingBuyN/AView Rating Details
6/3/2016Morgan StanleyReiterated RatingOverweightN/AView Rating Details
5/23/2016Bryan, Garnier & CoInitiated CoverageBuyN/AView Rating Details
3/30/2016Bank of America CorporationReiterated RatingBuyN/AView Rating Details
2/13/2016Northland SecuritiesReiterated RatingBuyN/AView Rating Details
2/8/2016Susquehanna Bancshares IncLower Price TargetPositive$280.00 -> $220.00N/AView Rating Details
1/18/2016Credit Suisse GroupUpgradeBuyN/AView Rating Details
10/21/2015William BlairReiterated RatingOutperform$276.00N/AView Rating Details
(Data available from 7/29/2015 forward)

Earnings

Earnings History for Shire PLC (NASDAQ:SHPG)
Earnings by Quarter for Shire PLC (NASDAQ:SHPG)
Earnings History by Quarter for Shire PLC (NASDAQ SHPG)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/3/2017$3.52$3.37N/AView Earnings Details
5/2/2017Q1 17$3.22$3.63$3.57 billionViewListenView Earnings Details
2/16/2017Q416$3.24$3.37$3.78 billion$3.81 billionViewN/AView Earnings Details
11/1/2016Q316$3.21$3.17$3.57 billion$3.45 billionViewN/AView Earnings Details
8/2/2016Q216$3.03$3.38$2.28 billion$2.43 millionViewN/AView Earnings Details
4/29/2016Q1$3.05$3.19$1.71 billion$1.71 billionViewListenView Earnings Details
2/11/2016Q415$2.89$2.97$1.69 million$1.72 billionViewListenView Earnings Details
10/23/2015Q315$2.87$3.24$1.63 billion$1.58 billionViewListenView Earnings Details
7/23/2015Q215$2.81$2.63$1.59 billion$1.56 billionViewListenView Earnings Details
4/30/2015Q115$2.56$2.84$1.47 billion$1.49 billionViewN/AView Earnings Details
2/12/2015Q115$2.68$2.63$1.53 billion$1.58 billionViewN/AView Earnings Details
10/24/2014Q314$2.47$2.93$1.46 billion$1.55 billionViewListenView Earnings Details
7/18/2014Q214$2.45$2.67$1.45 billion$1.50 billionViewN/AView Earnings Details
5/1/2014Q114$2.22$2.36$1.38 billion$1.35 billionViewN/AView Earnings Details
2/13/2014Q413$2.02$2.26$1.28 billion$1.33 billionViewN/AView Earnings Details
10/24/2013Q213$1.65$1.77$1.23 billion$1.24 billionViewN/AView Earnings Details
7/25/2013$1.60$1.79$1.21 billion$1.28 billionViewN/AView Earnings Details
5/2/2013Q113$1.56$1.63$1.21 billion$1.16 billionViewN/AView Earnings Details
2/14/2013Q412$1.58$1.58$1.20 billion$1.20 billionViewN/AView Earnings Details
10/25/2012$1.47$1.36ViewN/AView Earnings Details
8/1/2012$1.52$1.68ViewN/AView Earnings Details
4/26/2012$0.52$1.24ViewN/AView Earnings Details
2/9/2012$0.48$0.44ViewN/AView Earnings Details
10/28/2011$1.31$1.28ViewN/AView Earnings Details
7/28/2011$1.24$1.33ViewN/AView Earnings Details
4/28/2011$1.18$1.23ViewN/AView Earnings Details
2/10/2011$1.04$1.03ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Shire PLC (NASDAQ:SHPG)
2017 EPS Consensus Estimate: $14.75
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174$3.22$3.36$3.31
Q2 20174$3.53$3.69$3.60
Q3 20174$3.59$3.89$3.77
Q4 20174$3.81$4.26$4.07
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Shire PLC (NASDAQ:SHPG)
Most Recent Dividend:4/25/2017
Annual Dividend:$0.91
Dividend Yield:0.54%
Payout Ratio:122.97% (Trailing 12 Months of Earnings)
6.15% (Based on This Year's Estimates)
5.57% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Shire PLC (NASDAQ:SHPG)

Dividend History by Quarter for Shire PLC (NASDAQ SHPG)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/24/2017$0.773/8/20173/10/20174/25/2017
8/5/2016$0.149/7/20169/9/201610/7/2016
2/11/2016$0.673/9/20163/11/20164/12/2016
7/23/2015$0.139/2/20159/4/201510/2/2015
2/23/2015semiannual$0.570.48%3/11/20153/13/20154/14/2015
8/4/2014semiannual$0.110.09%9/3/20149/5/201410/3/2014
2/20/2014semiannual$0.510.61%3/5/20143/7/20144/8/2014
7/29/2013semiannual$0.090.16%9/4/20139/6/201310/3/2013
2/19/2013semiannual$0.440.92%3/6/20133/8/20134/9/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Shire PLC (NASDAQ:SHPG)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Shire PLC (NASDAQ:SHPG)
Latest Headlines for Shire PLC (NASDAQ:SHPG)
Source:
DateHeadline
americanbankingnews.com logoShire PLC (NASDAQ:SHPG) Short Interest Update
www.americanbankingnews.com - July 29 at 7:10 AM
thestreet.com logoShire Stock Rising on Takeover Talks - TheStreet.com
www.thestreet.com - July 28 at 7:55 AM
americanbankingnews.com logoShire PLC (NASDAQ:SHPG) to Release Earnings on Thursday
www.americanbankingnews.com - July 27 at 3:48 PM
streetinsider.com logoShire plc (SHPG) Said Back in Play - Standard - StreetInsider.com
www.streetinsider.com - July 27 at 7:24 AM
finance.yahoo.com logoShire Stock Rising on Takeover Talks
finance.yahoo.com - July 27 at 7:24 AM
prnewswire.com logoDrug Makers Stock Performance Review -- Alliqua BioMedical, Aerie Pharma, Shire, and Heron Therapeutics - PR Newswire (press release)
www.prnewswire.com - July 26 at 7:32 AM
seekingalpha.com logoDon't Lose The Faith In Shire - Seeking Alpha
seekingalpha.com - July 26 at 7:32 AM
finance.yahoo.com logoGap In Perceived and Actual Rates Of Prescription Stimulant Misuse, Abuse and Diversion Found Among College Students
finance.yahoo.com - July 26 at 7:32 AM
americanbankingnews.com logoShire PLC (SHPG) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 24 at 5:20 PM
americanbankingnews.com logoShire PLC (NASDAQ:SHPG) Expected to Earn FY2017 Earnings of $14.63 Per Share
www.americanbankingnews.com - July 20 at 9:53 AM
nasdaq.com logoExane Asset Management Buys Monsanto Co, Biogen Inc, Qiagen NV, Sells Citigroup Inc, W R Grace, ...
www.nasdaq.com - July 20 at 7:42 AM
americanbankingnews.com logoFY2018 EPS Estimates for Shire PLC (NASDAQ:SHPG) Decreased by Analyst
www.americanbankingnews.com - July 19 at 1:56 PM
americanbankingnews.com logoWilliam Blair Equities Analysts Lower Earnings Estimates for Shire PLC (SHPG)
www.americanbankingnews.com - July 19 at 9:57 AM
americanbankingnews.com logoMarinus Pharmaceuticals (MRNS) and Shire PLC (NASDAQ:SHPG) Critical Survey
www.americanbankingnews.com - July 18 at 10:19 PM
americanbankingnews.com logoQ2 2017 EPS Estimates for Shire PLC Decreased by SunTrust Banks (NASDAQ:SHPG)
www.americanbankingnews.com - July 18 at 9:35 AM
nasdaq.com logoShire Expands Broad Monoclonal Antibody Research Platform, Enters License Agreement for Novimmune Bi-specific ... - Nasdaq
www.nasdaq.com - July 18 at 8:08 AM
streetinsider.com logoShire plc (SHPG): Pressure Creates Buying Opportunity - BTIG - StreetInsider.com
www.streetinsider.com - July 18 at 8:08 AM
finance.yahoo.com logoShire Expands Broad Monoclonal Antibody Research Platform, Enters License Agreement for Novimmune Bi-specific Antibody
finance.yahoo.com - July 18 at 8:08 AM
finance.yahoo.com logoShire plc : Notice of Results
finance.yahoo.com - July 18 at 8:08 AM
americanbankingnews.com logoShire PLC (NASDAQ:SHPG) Given "Buy" Rating at BTIG Research
www.americanbankingnews.com - July 17 at 9:02 PM
americanbankingnews.com logoShire PLC (NASDAQ:SHPG) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - July 17 at 2:52 PM
americanbankingnews.com logoShire PLC (NASDAQ:SHPG) Receives Market Perform Rating from Sanford C. Bernstein
www.americanbankingnews.com - July 16 at 7:34 PM
americanbankingnews.com logoContrasting Shire PLC (NASDAQ:SHPG) and SciClone Pharmaceuticals (SCLN)
www.americanbankingnews.com - July 14 at 10:54 AM
finance.yahoo.com logo5 Pharma & Biotech Stocks That Could Be Big Winners in Q2 Earnings
finance.yahoo.com - July 13 at 9:29 AM
americanbankingnews.com logoShire PLC (NASDAQ:SHPG) Receives Buy Rating from Stifel Nicolaus
www.americanbankingnews.com - July 12 at 10:36 AM
americanbankingnews.com logo$3.75 Billion in Sales Expected for Shire PLC (SHPG) This Quarter
www.americanbankingnews.com - July 12 at 9:51 AM
streetinsider.com logoStifel Reiterates Buy on Shire plc (SHPG) Following Competitor Data Release - StreetInsider.com
www.streetinsider.com - July 12 at 7:59 AM
americanbankingnews.com logo$3.53 EPS Expected for Shire PLC (SHPG) This Quarter
www.americanbankingnews.com - July 10 at 6:18 PM
nasdaq.com logoShire Completes NDA Filing for Hemophilia Drug with FDA - Nasdaq
www.nasdaq.com - July 9 at 12:26 PM
americanbankingnews.com logoShire PLC (NASDAQ:SHPG) Upgraded by ValuEngine to "Buy"
www.americanbankingnews.com - July 8 at 2:52 PM
seekingalpha.com logoShire submits iNDA to FDA for SHP654 for treatment of Hemophilia A
seekingalpha.com - July 6 at 9:01 AM
nasdaq.com logoShire Submits Investigational NDA To FDA For Gene Therapy Candidate SHP654
www.nasdaq.com - July 6 at 9:01 AM
finance.yahoo.com logoShire plc : Additional Listing
finance.yahoo.com - July 6 at 9:01 AM
americanbankingnews.com logoEquities Analysts Set Expectations for Shire PLC's FY2017 Earnings (NASDAQ:SHPG)
www.americanbankingnews.com - July 6 at 8:44 AM
americanbankingnews.com logoShire PLC (SHPG) Rating Increased to Hold at HSBC Holdings plc
www.americanbankingnews.com - July 6 at 7:46 AM
feeds.benzinga.com logoShire submits investigational New Drug Application to FDA for Gene Therapy candidate SHP654 for treatment of Hemophilia A
feeds.benzinga.com - July 6 at 7:38 AM
finance.yahoo.com logo3 Reasons Sizzling-Hot Bioverativ Stock Can Go Even Higher
finance.yahoo.com - July 5 at 10:39 AM
finance.yahoo.com logoShire plc : Total voting rights
finance.yahoo.com - July 4 at 7:20 AM
finance.yahoo.com logoShire plc : Director/PDMR Shareholding
finance.yahoo.com - July 4 at 7:20 AM
americanbankingnews.com logoShire PLC (NASDAQ:SHPG) PT Set at $222.00 by Cantor Fitzgerald
www.americanbankingnews.com - July 3 at 6:25 PM
americanbankingnews.com logoShire PLC (SHPG) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - July 1 at 3:42 PM
americanbankingnews.com logoShire PLC (SHPG) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - June 27 at 2:39 PM
seekingalpha.com logoBiocryst and Shire under pressure on FDA approval of Behring's HAE med
seekingalpha.com - June 25 at 6:26 AM
americanbankingnews.com logoShire PLC (SHPG) Upgraded at BidaskClub
www.americanbankingnews.com - June 23 at 5:54 PM
feeds.benzinga.com logoSHIRE TO PRESENT NEW DATA AT ISTH 2017 TO ADVANCE THE STANDARD OF CARE IN HEMOPHILIA
feeds.benzinga.com - June 23 at 8:46 AM
seekingalpha.com logoEMA accepts Shire's marketing application for recombinant therapy for inherited bleeding disorder; shares ahead 2% premarket
seekingalpha.com - June 22 at 6:36 PM
streetinsider.com logoShire plc (SHPG) Granted Marketing Authorization from EMA for Veyvondi
www.streetinsider.com - June 22 at 6:36 PM
finance.yahoo.com logoShire wins FDA approval for new ADHD drug
finance.yahoo.com - June 22 at 6:35 PM
finance.yahoo.com logoShire Announces EMA Validation of Veyvondi Marketing Authorization Application for Treatment of Von Willebrand Disease
finance.yahoo.com - June 22 at 6:35 PM
streetinsider.com logoSupernus Pharma (SUPN) Announces Partner, Shire PLC (SHPG), Granted FDA Approval for Mydayis for ADHD - StreetInsider.com
www.streetinsider.com - June 22 at 1:34 PM

Social

Chart

Shire PLC (SHPG) Chart for Saturday, July, 29, 2017

This page was last updated on 7/29/2017 by MarketBeat.com Staff